Abbott Laboratories $ABT Holdings Trimmed by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 20.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 38,306 shares of the healthcare product maker’s stock after selling 10,008 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Abbott Laboratories were worth $3,786,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ballast Inc. bought a new position in Abbott Laboratories in the 3rd quarter valued at $216,000. Parkway Wealth Management Group LLC increased its stake in shares of Abbott Laboratories by 3.2% in the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock valued at $317,000 after buying an additional 98 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Abbott Laboratories by 2.6% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 255,880 shares of the healthcare product maker’s stock worth $25,289,000 after acquiring an additional 6,425 shares during the last quarter. Jeppson Wealth Management LLC raised its position in shares of Abbott Laboratories by 4.0% during the third quarter. Jeppson Wealth Management LLC now owns 15,382 shares of the healthcare product maker’s stock worth $1,520,000 after acquiring an additional 589 shares during the last quarter. Finally, CFS Investment Advisory Services LLC raised its position in shares of Abbott Laboratories by 7.4% during the third quarter. CFS Investment Advisory Services LLC now owns 17,930 shares of the healthcare product maker’s stock worth $1,760,000 after acquiring an additional 1,230 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter adjusted earnings per share were $1.42, in line with the company’s consensus estimate, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding expectations. Comparable sales increased 7%, and Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Management announced plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Glucerna, Pedialyte and PediaSure—into an independent, publicly traded company through a tax-free distribution to shareholders, targeted for completion by the end of 2027. Abbott believes the transaction could accelerate growth and expand margins in its remaining businesses. Abbott Nutrition separation announcement
• Positive Sentiment: New product approvals and European authorization for Abbott’s Cologuard Plus colorectal cancer test expand its diagnostics portfolio and could support longer-term growth. Cologuard Plus European approval
• Neutral Sentiment: The spin-off is intended to unlock value by allowing Abbott and the new Nutrition company to pursue separate strategies, but investors must assess execution, tax and transition risks before the separation is completed.
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in medical devices. The reduced outlook suggests near-term operating momentum may be softer than previously expected, despite continued strength in areas such as continuous glucose monitoring. Reuters report on Abbott’s outlook
• Negative Sentiment: Some analysts characterized the $1.42 adjusted EPS result as a slight miss against a $1.43 estimate. Combined with the lower sales outlook and uncertainty surrounding the Nutrition separation, that has outweighed the quarter’s revenue growth and caused the stock to decrease.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $100.59 on Thursday. The firm’s 50 day moving average price is $105.47 and its two-hundred day moving average price is $98.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The stock has a market cap of $174.06 billion, a PE ratio of 32.55, a PEG ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting the consensus estimate of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.30 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.53 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s payout ratio is 81.55%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Citigroup raised their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. TD Cowen reiterated a “buy” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research report on Friday, October 16th. Barclays initiated coverage on Abbott Laboratories in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.88.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.